$APLS
Apellis Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024121062 Filed on November 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $196.8M $146.4M
YoY Change 78.29% 545.89%
Cost Of Revenue $33.56M $19.91M
YoY Change 49.81% 580.75%
Gross Profit $163.3M $126.5M
YoY Change 85.54% 540.72%
Gross Profit Margin 82.95% 86.4%
Selling, General & Admin $122.0M $141.7M
YoY Change -16.22% 67.96%
% of Gross Profit 74.71% 112.05%
Research & Development $88.57M $69.28M
YoY Change 11.52% -30.32%
% of Gross Profit 54.25% 54.78%
Depreciation & Amortization $457.0K $476.0K
YoY Change -0.65% 22.68%
% of Gross Profit 0.28% 0.38%
Operating Expenses $244.1M $211.0M
YoY Change -1.36% 14.8%
Operating Profit -$47.28M -$84.52M
YoY Change -65.51% -48.48%
Interest Expense -$9.643M -$2.854M
YoY Change 319.26% -9.77%
% of Operating Profit
Other Income/Expense, Net $70.00K $219.0K
YoY Change -111.61% -189.02%
Pretax Income -$56.85M -$87.15M
YoY Change -59.39% -47.96%
Income Tax $600.0K $1.423M
% Of Pretax Income
Net Earnings -$57.45M -$88.58M
YoY Change -59.04% -46.64%
Net Earnings / Revenue -29.19% -60.51%
Basic Earnings Per Share -$0.46
Diluted Earnings Per Share -$0.46 -$0.73
COMMON SHARES
Basic Shares Outstanding 124.4M 121.8M 118.5M
Diluted Shares Outstanding 124.2M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $396.9M $351.2M
YoY Change -12.28% -36.36%
Cash & Equivalents $396.9M $351.2M
Short-Term Investments
Other Short-Term Assets $11.78M $22.41M
YoY Change -61.81% -38.87%
Inventory $121.1M $146.4M
Prepaid Expenses $23.81M $38.82M
Receivables $279.0M $206.4M
Other Receivables $4.958M $18.05M
Total Short-Term Assets $833.9M $766.3M
YoY Change 4.66% 6.51%
LONG-TERM ASSETS
Property, Plant & Equipment $3.379M $4.345M
YoY Change -29.46% -29.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.450M $1.309M
YoY Change 23.4% -91.71%
Total Long-Term Assets $67.97M $22.40M
YoY Change 216.89% -44.96%
TOTAL ASSETS
Total Short-Term Assets $833.9M $766.3M
Total Long-Term Assets $67.97M $22.40M
Total Assets $901.9M $788.7M
YoY Change 10.22% 3.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $42.73M $37.52M
YoY Change 134.88% 0.47%
Accrued Expenses $139.8M $127.8M
YoY Change 19.43% 34.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $75.83M
YoY Change -100.0% 157.02%
Total Short-Term Liabilities $191.3M $247.6M
YoY Change 3.03% 47.72%
LONG-TERM LIABILITIES
Long-Term Debt $452.2M $332.9M
YoY Change 16.41% -18.5%
Other Long-Term Liabilities $9.829M $2.312M
YoY Change 939.01% -83.89%
Total Long-Term Liabilities $9.829M $2.312M
YoY Change 939.01% -99.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $191.3M $247.6M
Total Long-Term Liabilities $9.829M $2.312M
Total Liabilities $664.7M $594.2M
YoY Change 13.45% 0.65%
SHAREHOLDERS EQUITY
Retained Earnings -$3.000B -$2.800B
YoY Change 11.11% 21.74%
Common Stock $12.00K $12.00K
YoY Change 0.0% 9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $237.1M $194.5M
YoY Change
Total Liabilities & Shareholders Equity $901.9M $788.7M
YoY Change 10.22% 3.75%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$57.45M -$88.58M
YoY Change -59.04% -46.64%
Depreciation, Depletion And Amortization $457.0K $476.0K
YoY Change -0.65% 22.68%
Cash From Operating Activities $34.10M -$97.88M
YoY Change -120.17% -30.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $95.00K
YoY Change -100.0% -88.84%
Acquisitions
YoY Change
Other Investing Activities $99.00K
YoY Change -99.92%
Cash From Investing Activities $0.00 $4.000K
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.542M -3.913M
YoY Change -55.71% -75.46%
NET CHANGE
Cash From Operating Activities 34.10M -97.88M
Cash From Investing Activities 0.000 4.000K
Cash From Financing Activities 2.542M -3.913M
Net Change In Cash 36.64M -101.8M
YoY Change -122.42% 212.59%
FREE CASH FLOW
Cash From Operating Activities $34.10M -$97.88M
Capital Expenditures $0.00 $95.00K
Free Cash Flow $34.10M -$97.97M
YoY Change -120.16% -30.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001492422
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38276
dei Entity Registrant Name
EntityRegistrantName
APELLIS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1537290
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Fifth Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
977-5700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
APLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124393017
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
396864000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
351185000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
279011000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
206442000
CY2024Q3 us-gaap Inventory Net
InventoryNet
121058000
CY2023Q4 us-gaap Inventory Net
InventoryNet
146362000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23809000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38820000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1373000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1114000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11782000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22408000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
833897000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
766331000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17060000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16745000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3379000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4345000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
46080000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1450000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1309000
CY2024Q3 us-gaap Assets
Assets
901866000
CY2023Q4 us-gaap Assets
Assets
788730000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
42730000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
37516000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
139835000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127806000
CY2023Q4 apls Development Liability Current
DevelopmentLiabilityCurrent
75830000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6792000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6441000
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
1903000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
191260000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
247593000
CY2023Q4 apls Development Liability Noncurrent
DevelopmentLiabilityNoncurrent
239817000
CY2024Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
358982000
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
93263000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
93033000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11411000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11454000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9829000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2312000
CY2024Q3 us-gaap Liabilities
Liabilities
664745000
CY2023Q4 us-gaap Liabilities
Liabilities
594209000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
122069000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122069000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119556000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119556000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3239262000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3035539000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3140000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3542000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2999013000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2837488000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
237121000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
194521000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
901866000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
788730000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196830000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
110399000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
568839000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250214000
CY2024Q3 apls Operating Cost Of Sales
OperatingCostOfSales
33557000
CY2023Q3 apls Operating Cost Of Sales
OperatingCostOfSales
22410000
apls Operating Cost Of Sales
OperatingCostOfSales
76867000
apls Operating Cost Of Sales
OperatingCostOfSales
38598000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88569000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79421000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
251216000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
285105000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
121984000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145648000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
379571000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
359114000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
244110000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
247479000
us-gaap Operating Expenses
OperatingExpenses
707654000
us-gaap Operating Expenses
OperatingExpenses
682817000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-47280000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-137080000
us-gaap Operating Income Loss
OperatingIncomeLoss
-138815000
us-gaap Operating Income Loss
OperatingIncomeLoss
-432603000
apls Loss On Extinguishment Of Development Liability
LossOnExtinguishmentOfDevelopmentLiability
1949000
CY2024Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2889000
CY2023Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4989000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
9377000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
16385000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12532000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7310000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
28857000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
22179000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-603000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-405000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-946000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56853000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-140004000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-160649000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-439343000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
592000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
233000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
876000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
709000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-57445000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-140237000
us-gaap Net Income Loss
NetIncomeLoss
-161525000
us-gaap Net Income Loss
NetIncomeLoss
-440052000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
222000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-269000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
402000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-190000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
222000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-269000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
402000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57223000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-140506000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-161123000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-440242000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.73
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124234000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124234000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120292000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120292000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123698000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123698000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117827000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117827000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
194521000
CY2024Q1 apls Proceeds From Settlement Of Capped Call
ProceedsFromSettlementOfCappedCall
98763000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9477000
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-28000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30349000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-66423000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
266676000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1962000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29990000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3193000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-37657000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
163000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
264327000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2556000
CY2024Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-14000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27475000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-57445000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
222000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
237121000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169872000
CY2023Q1 apls Issuance Of Common Stock And Pre Funded Warrants In Common Stock Offering
IssuanceOfCommonStockAndPreFundedWarrantsInCommonStockOffering
384387000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17718000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-10999000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28823000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-177778000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412123000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22334000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-27000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29277000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3754000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-122037000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
345403000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5757000
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-9000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21626000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-140237000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-269000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
232271000
us-gaap Profit Loss
ProfitLoss
-161525000
us-gaap Profit Loss
ProfitLoss
-440052000
us-gaap Share Based Compensation
ShareBasedCompensation
87814000
us-gaap Share Based Compensation
ShareBasedCompensation
79726000
apls Loss On Extinguishment Of Development Liability
LossOnExtinguishmentOfDevelopmentLiability
1949000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-152000
us-gaap Depreciation
Depreciation
1350000
us-gaap Depreciation
Depreciation
1308000
apls Amortization Of Discounts For Credit Facility
AmortizationOfDiscountsForCreditFacility
742000
apls Amortization Of Discounts For Convertible Notes
AmortizationOfDiscountsForConvertibleNotes
230000
apls Amortization Of Discounts For Convertible Notes
AmortizationOfDiscountsForConvertibleNotes
222000
apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
8936000
apls Accretion Of Discount To Development Liability
AccretionOfDiscountToDevelopmentLiability
19491000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
72569000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
161542000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20776000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12831000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-15022000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7681000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-10651000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5981000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
81000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-14811000
apls Increase Decrease In Right Of Use Assets And Lease Liabilities
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities
-7000
apls Increase Decrease In Right Of Use Assets And Lease Liabilities
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities
-94000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-399000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19450000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
19534000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
23099000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1903000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107226000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-496860000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
383000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
678000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-383000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-678000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
365454000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1589000
apls Repayment Of Development Liability
RepaymentOfDevelopmentLiability
326533000
apls Proceeds From Settlement Of Capped Call
ProceedsFromSettlementOfCappedCall
98763000
apls Proceeds From Issuance Of Common Stock And Pre Funded Warrant Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantOfferingNetOfIssuanceCosts
384387000
apls Payments For Development Liability
PaymentsForDevelopmentLiability
24500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13995000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45809000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3193000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3754000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
42000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
11038000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153241000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
398412000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
306000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-449000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45938000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-99575000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
352299000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
553075000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
398237000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
453500000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
396864000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452414000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
1373000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1086000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
398237000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
453500000
us-gaap Interest Paid Net
InterestPaidNet
19446000
us-gaap Interest Paid Net
InterestPaidNet
3286000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
600000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
578000
apls Issuance Costs For Credit Facility Incurred But Not Yet Paid
IssuanceCostsForCreditFacilityIncurredButNotYetPaid
5625000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Organization and Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”) and SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration (“GA”).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. From inception to September 30, 2024, the Company has incurred cash outflows from operations, losses from operations and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> primarily as a result of expenses incurred through a combination of research and development activities related to the Company’s various product candidates and expenses supporting those activities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of November 5, 2024, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">396.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, combined with cash anticipated to be generated from sales of EMPAVELI and SYFOVRE will be sufficient to fund its operations and capital expenditures for at least the next twelve months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3000000000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
396900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development liability, accrued expenses, prepaid expenses, convertible debt, reserves for variable consideration, reserves for excess or obsolete inventories, and income taxes.</span></p>
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
279000000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
206400000
us-gaap Proceeds From Sale Of Other Receivables
ProceedsFromSaleOfOtherReceivables
56590000
apls Payment Of Factoring Fees
PaymentOfFactoringFees
672000
apls Proceeds From Sale Of Other Receivables Net Of Factoring Fees
ProceedsFromSaleOfOtherReceivablesNetOfFactoringFees
55918000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
46639000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
32724000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
113708000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
82924000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6791000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
30714000
CY2024Q3 apls Inventory
Inventory
167138000
CY2023Q4 apls Inventory
Inventory
146362000
us-gaap Inventory Write Down
InventoryWriteDown
14100000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
9300000
CY2024Q3 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
8251000
CY2023Q4 apls Down Payments For Inventory Current
DownPaymentsForInventoryCurrent
16296000
CY2024Q3 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
6582000
CY2023Q4 apls Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
13931000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8976000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8593000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23809000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38820000
CY2024Q3 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
4958000
CY2023Q4 apls Royalties Receivable Current
RoyaltiesReceivableCurrent
3054000
CY2023Q4 apls Receivable From Collaboration Agreement Current
ReceivableFromCollaborationAgreementCurrent
15000000
CY2024Q3 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
6824000
CY2023Q4 apls Deposits And Other Current Assets
DepositsAndOtherCurrentAssets
4354000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11782000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22408000
CY2024Q1 apls Development Cost Reimbursement Received
DevelopmentCostReimbursementReceived
15000000
CY2024Q3 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
24509000
CY2023Q4 apls Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
28318000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6676000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
10197000
CY2024Q3 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
34722000
CY2023Q4 apls Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
51781000
CY2024Q3 apls Accrued Goods Received Not Invoiced Current
AccruedGoodsReceivedNotInvoicedCurrent
19623000
CY2023Q4 apls Accrued Goods Received Not Invoiced Current
AccruedGoodsReceivedNotInvoicedCurrent
5902000
CY2024Q3 apls Product Revenue Reserves Current
ProductRevenueReservesCurrent
32901000
CY2023Q4 apls Product Revenue Reserves Current
ProductRevenueReservesCurrent
16625000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21404000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14983000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
139835000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127806000
us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
25340.5000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17060000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16745000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
18203000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17895000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M2D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.063
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1700000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1800000
us-gaap Operating Lease Cost
OperatingLeaseCost
5600000
us-gaap Operating Lease Cost
OperatingLeaseCost
5200000
us-gaap Operating Lease Payments
OperatingLeasePayments
5992000
us-gaap Operating Lease Payments
OperatingLeasePayments
6186000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1966000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7421000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6763000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2064000
CY2024Q3 apls Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
1485000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19699000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1496000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
18203000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
apls Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities
0.50
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q3 apls Number Of Licensed Products
NumberOfLicensedProducts
2
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14459000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16566000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-121062-index-headers.html Edgar Link pending
0000950170-24-121062-index.html Edgar Link pending
0000950170-24-121062.txt Edgar Link pending
0000950170-24-121062-xbrl.zip Edgar Link pending
apls-20240930.htm Edgar Link pending
apls-20240930.xsd Edgar Link pending
apls-ex31_1.htm Edgar Link pending
apls-ex31_2.htm Edgar Link pending
apls-ex32_1.htm Edgar Link pending
apls-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
apls-20240930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable